Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.

On January 28, 2025, the Company received clearance of its IND from the FDA to initiate a first-in-human Phase 1 dose escalation clinical trial to evaluate one of its lead drug candidates, HCW9302, in ...

BMS-986458 features three stereocenters, one of which epimerizes easily, Mortensen said. The drug candidate, which would be ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

The world urgently needs new antibiotics. In 2019 alone, antibiotic-resistant bacteria killed more than 4.5 million people ...

Researchers discovered lariocidin, a lasso peptide antibiotic that kills multidrug-resistant bacteria by binding a novel ...

The Global Single-cell Analysis Market is projected to grow at a CAGR of 9.5% from 2026 to 2033, according to a new report published by Verified Market Reports ®. The report reveals that the market ...

The author writes "The U.S. International Trade Commission (ITC) continues to act as a key venue for intellectual property ...

Building the world’s largest biobank with data from global populations to accelerate biomarker and drug discovery and development of ...

Scientists believe the hypertension drug rilmenidine could also act as ... A key part of the discovery revolves around a biological receptor called nish-1, which appears to be essential for ...

His profanity-packed speeches and death threats to drug gangs were a feature of his successful campaign for the presidency in 2016. Among his statements during the campaign were: "Forget the laws ...